25,632 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,632 shares of the biopharmaceutical company's stock, valued at approximately $871,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in CLDX. Vanguard Group Inc. increased its position in Celldex Therapeutics by 19.8% during the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company's stock valued at $153,215,000 after purchasing an additional 604,251 shares during the period. Point72 Asset Management L.P. increased its holdings in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company's stock valued at $71,725,000 after buying an additional 654,194 shares during the period. Marshall Wace LLP increased its holdings in Celldex Therapeutics by 53.3% during the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company's stock valued at $50,995,000 after buying an additional 479,068 shares during the period. Jennison Associates LLC raised its stake in Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock worth $45,017,000 after buying an additional 321,325 shares in the last quarter. Finally, Novo Holdings A S lifted its holdings in Celldex Therapeutics by 13.4% during the third quarter. Novo Holdings A S now owns 963,663 shares of the biopharmaceutical company's stock worth $32,755,000 after buying an additional 113,663 shares during the period.

Insider Activity

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the stock in a transaction on Monday, November 11th. The stock was bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares in the company, valued at $1,080,416.88. The trade was a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.80% of the company's stock.

Celldex Therapeutics Stock Down 1.6 %

CLDX stock traded down $0.45 during trading on Friday, reaching $27.44. The company had a trading volume of 340,442 shares, compared to its average volume of 884,444. Celldex Therapeutics, Inc. has a twelve month low of $22.93 and a twelve month high of $53.18. The firm has a 50-day simple moving average of $29.09 and a 200-day simple moving average of $34.55.

Analyst Ratings Changes

CLDX has been the topic of a number of analyst reports. Wells Fargo & Company upgraded Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 26th. Citigroup initiated coverage on Celldex Therapeutics in a research note on Monday, October 7th. They issued a "buy" rating and a $70.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, November 20th. The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a "neutral" rating and a $45.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Celldex Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $62.25.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.